Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1328Carcinoma, Hepatocellular 782Stomach Neoplasms 720Pancreatic Neoplasms 701Colonic Neoplasms 533Rectal Neoplasms 472Esophageal Neoplasms 422Liver Neoplasms 320Neoplasms 264Breast Neoplasms 221Lung Neoplasms 188Gastrointestinal Neoplasms 164Cholangiocarcinoma 150Barrett Esophagus 116Prostatic Neoplasms 107Neoplasm Metastasis 105Ovarian Neoplasms 89Carcinoma, Non-Small-Cell Lung 80Anus Neoplasms 77Melanoma 72Esophageal Squamous Cell Carcinoma 71Disease 71Head and Neck Neoplasms 70Colorectal Neoplasms, Hereditary Nonpolyposis 67Biliary Tract Neoplasms 67Gastrointestinal Stromal Tumors 66Liver Cirrhosis 60Gallbladder Neoplasms 58Recurrence 57Uterine Cervical Neoplasms 56

Interventions

regorafenib 1HMPL-013 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × TAS 102 × Gastrointestinal × Clear all
NCT05993702 2023-08-15

TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer

China Medical University, China

Unknown
45 enrolled
Gastrointestinal

TAS 102

Data powered by HemOnc (CC BY 4.0) Colophon âš¡